October 29, 2020 | ~Home Feature| Media Coverage

Cell & Gene

Castle Creek Biosciences’ D-Fi To Be Manufactured At In-House cGMP

Read More

October 28, 2020 | ~Home Feature| Press Release

Castle Creek Biosciences Announces First Patient Dosed in DeFi-RDEB Phase 3 Clinical Trial of Debcoemagene Autoficel (D-Fi) Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Company manufacturing and distributing D-Fi at in-house, cGMP commercial-scale facility in greater Philadelphia area

Read More

October 20, 2020 | ~Home Feature| Media Coverage

Scleroderma News

First Patient Treated in Trial Testing FCX-013 Gene Therapy for Localized Scleroderma

Read More

October 15, 2020 | ~Home Feature| Press Release

Castle Creek Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of FCX-013 Gene Therapy for Treatment of Moderate to Severe Localized Scleroderma

Study targets a chronic autoimmune skin disorder affecting approximately 50,000 patients in the U.S.

Read More

February 29, 2020 | ~Home Feature| Media Coverage

Philadelphia Magazine’s NextHealth PHL

NextUp: “The Company Using Gene Therapy to Cure Rare Skin Conditions” John Maslowski, CEO, Castle Creek Biosciences

Read More